

ORIGINAL ARTICLE

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

Niantao Deng,^{1,2} Liang Kee Goh,^{1,3,4} Hannah Wang,¹ Kakoli Das,¹ Jiong Tao,^{1,5} Iain Beehuat Tan,^{1,2,4} Shenli Zhang,¹ Minghui Lee,⁶ Jeanie Wu,⁶ Kiat Hon Lim,⁷ Zhengdeng Lei,⁸ Glenn Goh,¹ Qing-Yan Lim,⁹ Angie Lay-Keng Tan,¹ Dianne Yu Sin Poh,¹ Sudep Riahi,¹⁰ Sandra Bell,¹⁰ Michael M Shi,¹¹ Ronald Linnartz,¹¹ Feng Zhu,¹² Khay Guan Yeoh,¹² Han Chong Toh,⁴ Wei Peng Yong,¹³ Hyun Cheol Cheong,¹⁴ Sun Young Rha,¹⁴ Alex Boussioutas,¹⁵ Heike Grabsch,¹⁶ Steve Rozen,⁸ Patrick Tan^{1,6,17,18}

See Commentary, p 638

► Additional materials are published online only. To view these files please visit the journal online (<http://gut.bmj.com/content/61/5.toc>).

For numbered affiliations see end of article.

Correspondence to

Dr Patrick Tan, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore; gmstanp@duke-nus.edu.sg

Accession number in NCBI GEO database: GSE31168.

Revised 9 January 2012
Accepted 10 January 2012
Published Online First
7 February 2012



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://gut.bmj.com/site/about/unlocked.xhtml>

ABSTRACT

Objective Gastric cancer is a major gastrointestinal malignancy for which targeted therapies are emerging as treatment options. This study sought to identify the most prevalent molecular targets in gastric cancer and to elucidate systematic patterns of exclusivity and co-occurrence among these targets, through comprehensive genomic analysis of a large panel of gastric cancers.

Design Using high-resolution single nucleotide polymorphism arrays, copy number alterations were profiled in a panel of 233 gastric cancers (193 primary tumours, 40 cell lines) and 98 primary matched gastric non-malignant samples. For selected alterations, their impact on gene expression and clinical outcome were evaluated.

Results 22 recurrent focal alterations (13 amplifications and nine deletions) were identified. These included both known targets (*FGFR2*, *ERBB2*) and also novel genes in gastric cancer (*KLF5*, *GATA6*). Receptor tyrosine kinase (RTK)/RAS alterations were found to be frequent in gastric cancer. This study also demonstrates, for the first time, that these alterations occur in a mutually exclusive fashion, with *KRAS* gene amplifications highlighting a clinically relevant but previously underappreciated gastric cancer subgroup. *FGFR2*-amplified gastric cancers were also shown to be sensitive to dovitinib, an orally bioavailable FGFR/VEGFR targeting agent, potentially representing a subtype-specific therapy for *FGFR2*-amplified gastric cancers.

Conclusion The study demonstrates the existence of five distinct gastric cancer patient subgroups, defined by the signature genomic alterations *FGFR2* (9% of tumours), *KRAS* (9%), *EGFR* (8%), *ERBB2* (7%) and *MET* (4%). Collectively, these subgroups suggest that at least 37% of gastric cancer patients may be potentially treatable by RTK/RAS directed therapies.

Gastric adenocarcinoma, or gastric cancer is a leading cause of global cancer mortality with an overall 5-year survival rate of approximately 20%.^{1,2} Particularly prevalent in many Asian countries,³

Significance of this study

What is already known about this subject?

- Gastric cancer patients with *ERBB2*-amplified tumours can clinically benefit from *ERBB2*-targeted therapies. Similar to *ERBB2*, several other molecularly targeted therapies are currently being evaluated in gastric cancer.
- Little is known regarding which molecular targets are concurrently expressed in the same gastric tumours, or independently in different tumours.
- Unlike other cancer types, activating mutations in *KRAS* are also rarely observed in gastric cancer.

What are the new findings?

- This study identified 22 recurrent genomic alterations in gastric cancer, comprising both known gastric cancer targets (*FGFR2*, *ERBB2*) and genes not previously reported to be amplified in gastric cancer (*KLF5*, *GATA6*).
- Genes related to RTK/RAS signalling, in particular *FGFR2*, *KRAS*, *ERBB2*, *EGFR* and *MET* are frequently amplified in gastric cancer in a mutually exclusive manner.
- *FGFR2*-amplified gastric cancers exhibited sensitivity to dovitinib, an orally bioavailable targeted therapy.
- *KRAS* amplifications, frequently observed in gastric cancer, are significantly associated with adverse prognosis.

most gastric cancer patients present at advanced disease stages and are treated by palliative chemotherapy, with median survival times of 11–12 months.⁴ In addition to standard cytotoxic regimens, targeted therapies, which are small molecules or antibodies designed to disrupt the activity of

Significance of this study

How might it impact on clinical practice in the foreseeable future?

- ▶ Dovitinib may represent a subtype-specific therapy for *FGFR2*-amplified gastric cancers.
- ▶ *KRAS* genomic amplification status should be assessed in clinical trials involving therapies targeting upstream RTK.
- ▶ Genomic amplifications in RTK/RAS components define five distinct gastric cancer molecular subgroups, to which differing therapies can be allocated. In total, 37% of the gastric cancer population may be treatable by RTK/RAS targeting agents.

specific oncogenic signalling pathways, have recently emerged as a promising therapeutic strategy. In the recent ToGA trial,⁴ trastuzumab, an anti-*HER2/ERBB2* targeting antibody, improved the overall survival of patients with *HER2*-positive tumours when combined with chemotherapy. However, because only 7–17% of gastric cancer patients are *HER2* positive (either gene amplification or overexpression) and thus suitable candidates for anti-*HER2* therapy,^{5–7} further research is warranted to increase the population of gastric cancer patients for which targeted treatments are clinical options.

Reflecting this urgency, several other targeted therapies are currently undergoing preclinical and clinical testing in gastric cancer, directed against diverse oncogenic proteins including signalling receptors, histone deacetylases and cellular proteins.^{8–10} However, because most of these targeted therapies were originally designed against proteins expressed or discovered in other cancers (eg, trastuzumab for breast cancer), in many cases surprisingly little is actually known either regarding the true prevalence of their oncogenic targets in primary gastric cancers, or if expression of these oncogenic targets is correlated with key clinico-pathological parameters such as patient outcome. As one example, the *FGFR2* receptor tyrosine kinase (RTK) has previously been proposed as a potential therapeutic target in gastric cancer.¹¹ However, most *FGFR2*-related studies in gastric cancer have been primarily restricted to in-vitro cultured cell lines,^{12–15} and little data is available regarding the true prevalence of *FGFR2* gene amplification in primary gastric cancers particularly at the high-resolution genomic level. As such, a comprehensive and unbiased survey to identify the most prevalent molecular targets in gastric cancer could facilitate many aspects of gastric cancer translational research, for example, in focusing clinical trials efforts on those therapies that might benefit the greatest numbers of gastric cancer patients.

Besides identifying the most prevalent targets, recent findings have also highlighted the importance of determining if certain combinations of targets are expressed either independently from one another (ie, mutual exclusivity) or co-occurring in the same tumour. Knowledge of such 'inter-target relationships' (ITR) can shed critical insights into the signalling networks of a cancer cell, case examples being the mutual exclusivity of *KRAS* and *BRAF* activating mutations in colorectal cancer, and the exclusivity of *EGFR* and *KRAS* mutations in lung cancer.^{14–15} Identifying ITR may also highlight promising drug combinations for combination therapy, and suggest rational molecular criteria for patient inclusion and exclusion in clinical trials. Recent studies exemplifying both the basic and clinical importance of ITR include *ERBB2* and *PIK3CA*, in which co-occurring *PIK3CA* mutations in *ERBB2*-positive breast cancers can modulate clinical responses to

trastuzumab,¹⁶ and *EGFR* and *MET*, in which clinical resistance to gefitinib in *EGFR*-mutated lung cancers can be caused by co-existing *MET* gene amplifications.¹⁷

In this study, we sought to identify the most prevalent molecular targets in gastric cancer and to elucidate their ITR. To achieve this aim, we performed, to our knowledge, the largest and most comprehensive survey of genomic copy number alterations in gastric cancer to date, profiling more than 230 gastric cancers (>190 primary tumours and 40 cell lines) on high resolution single nucleotide polymorphism (SNP) arrays containing over 1 million array probes.

MATERIALS AND METHODS

Patient samples were obtained from institutional tissue repositories of the participating centres. Primary gastric tumours were collected with approvals from the respective institutional research ethics review committees and with signed patient informed consent. 'Normal' (ie, non-malignant) samples used in this study refer to samples harvested from the stomach, from sites distant from the tumour and exhibiting no visible evidence of tumour or intestinal metaplasia/dysplasia upon surgical assessment. Clinicopathological information of these patients including age, disease stage, histological subtype, treatment and anatomical location, are included in supplementary table S1 (available online only). Only three patients received neo-adjuvant or preoperative chemotherapy before surgery. Gastric cancer cell lines were obtained from commercial sources (American Type Culture Collection, Japan Health Science Research Resource Bank) or from collaborators (Yonsei Cancer Centre, South Korea). Genomic DNA were extracted from flash-frozen tissues or cell pellets using a Qiagen genomic DNA extraction kit (Qiagen, Hilden, Germany), and profiled on Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, California, USA) according to the manufacturer's specifications. The array data have been deposited into the National Centre for Biotechnology Information's Gene Expression Omnibus under accession number GSE31168. Tumour-specific genomic alterations were identified by normalising the primary gastric cancer profiles against the primary matched gastric normal samples. Analyses were performed using the genomic identification of significant targets in cancer (GISTIC) algorithm¹⁸ using false discovery rate q-value thresholds of less than 0.25 for broad regions and less than 0.001 for focal regions, similar to those used in previous reports.^{19–21}

Additional details, including methods associated with dimension reduction permutation (DRP), fluorescence in-situ hybridisation (FISH) assays, and functional assays, are presented in the supplementary materials (available online only).


RESULTS**Genomic landscape of Copy Number Alteration (CNA) in gastric cancer**

We profiled genomic DNA samples from 193 primary gastric cancers, 98 primary matched gastric normal samples and 40 gastric cancer cell lines on Affymetrix SNP6 microarrays containing approximately 1.8 million probes with a median interprobe spacing of 680 bp. To identify tumour-specific genomic alterations and exclude regions of potential germ line copy number variation, we normalised the gastric cancer profiles against the matched gastric normal samples (see the Methods section and supplementary figure S1 (available online only) for representative profiles). On average, we observed approximately 150 genomic aberrations per gastric cancer, comprising a mixture of broad and focally altered regions. Frequently amplified broad chromosomal regions included 1q, 3q, 5p, 6p, 7p, 8q, 12p, 13q,

18pq, 19p, 20pq and 21p (frequencies 9.8–33.7%), and frequently deleted chromosomal regions included 3p, 4pq, 5q, 6q, 8p, 9p, 9q, 11q, 12p, 14q, 16q, 17p, 18p, 18q, 19p 21q and 22q

(frequencies 7.8–13.0%) (figure 1A). These results are highly concordant with previous comparative genomic hybridisation (CGH/aCGH) studies of gastric cancer.^{22–27}

Figure 1 Broad and focal genomic alterations in gastric cancer. (A) Large-scale copy number alterations. The diagram shows a CNA plot where chromosomal regions of the 22 autosomes are represented on the y-axis, and genomic identification of significant targets in cancer (GISTIC) computed false discovery rate (FDR) q-values are on the x-axis. Chromosomal deletions are on the left (blue) and amplifications are on the right (red). Significantly altered regions of broad CNA are highlighted at the sides, as blue and red bars (GISTIC q value <0.25). (B) Focal alterations. Genes localised within the peaks of the focally altered regions are specified. Genes in square brackets are genes that lie immediately adjacent to the alteration peak (eg, *MYC*). Significantly altered focal events (GISTIC q-value <0.001) are highlighted at the sides and summarised in table 1.



Focal genomic alterations highlight 22 potential targets in gastric cancer

We identified 22 focal genomic alterations, defined as narrow regions (typically <100 kb) exhibiting high levels of copy number gain or loss (table 1). Among the amplified genes were several oncogenes previously known to be amplified in gastric cancer, including *EGFR*, *ERBB2/HER2* and *CCND1* (figure 1B).^{6 28 29} Among the focally deleted genes in gastric cancer, we re-identified *FHIT*, *RB1*, *CDKN2A/B*, and *WWOX*, also previously known to be deleted in gastric cancer.^{30–34} The re-discovery of these classic oncogenes and tumour suppressor genes supports the accuracy of the SNP6 array data. To validate the array data further, we performed *ERBB2* immunohistochemistry on 146 of the 193 cases (see supplementary figure S2, available online only), and confirmed a significant association between *ERBB2* copy number gain and *ERBB2* protein expression ($p < 0.01$, Fisher's exact test, supplementary table S2, available online only).

Besides known genes, the analysis also revealed novel genes not previously reported in gastric cancer. These included genomic amplification of the transcription factors *GATA6* and *KLF5*, and somatic deletions in *PARK2*, *PDE4D*, *CSMD1* and *GMDS*. Recent data suggest that GATA factors in particular may play an oncogenic role in certain gastrointestinal cancers, for example, *GATA6* has been shown to be amplified in pancreatic cancer.³⁵ *PARK2* and *PDE4D* deletions have also recently been observed in glioblastoma and lung adenocarcinomas.^{19 20} Using immunohistochemistry, we confirmed that one of these novel deleted genes, *CSMD1*, was downregulated or absent in approximately 40% of primary gastric cancers at the protein

level, but was highly expressed in normal gastric epithelium ($n=42$; supplementary figure S3, available online only).

A network of non-random ITR define relationships between gastric cancer targets

A major goal of our study was to identify non-coincidental ITR between the 22 gastric cancer targets in a systematic, unbiased and statistically rigorous manner. We developed a statistical method called DRP for this purpose. Briefly, DRP identifies non-random ITR between targets by comparing the numbers of tumour samples exhibiting a particular ITR (associations between distinct alterations) against a null distribution of background ITR generated through random permutation. The supplementary information (available online only) provides a detailed description of the DRP method. Compared with other methods such as hierarchical clustering and correlation tests, DRP provides additional sensitivity in identifying ITR, without requiring a priori knowledge of specific gene functions (see supplementary figure S4, available online only).

We uncovered several significant ITR associated with the 22 gastric cancer targets. These target pairs were either amplified in a mutually exclusive manner in different tumours, or co-amplified in the same tumour (figure 2 and supplementary table S3, available online only). Functionally, the gastric cancer ITR tended to involve two specific target classes—genes related to RTK/RAS signalling, including *KRAS*, *FGFR2*, *ERBB2*, *EGFR* and *MET*, and genes related to transcription factor biology (*MYC*, *GATA4*, *GATA6* and *KLF5*). For example, tumours exhibiting *KRAS* amplifications were largely distinct from tumours exhibiting *ERBB2* or *FGFR2* amplification ($p=0.02$ and $p=0.005$ for

Table 1 Focal regions of CNA regions in gastric cancer

CNA	Chr	Start	End	Length (kb)	Cytoband	Q value	Genes in peak
Amplification							
1	10	123 336 181	123 337 713	1.5	10q26.13	3.9561E-99	FGFR2
2	8	128 628 340	128 670 251	41.9	8q24.21	7.984E-27	[MYC]
3	19	34 982 652	35 002 397	19.7	19q12	3.1439E-23	CCNE1
4	12	25 213 920	25 336 398	122.5	12p12.1	1.5713E-14	KRAS , <i>CASC1</i> , <i>LYRM5</i>
5	18	17 947 474	18 040 783	93.3	18q11.2	1.0616E-13	<i>GATA6</i>
6	5	21 377 838	21 406 308	28.5	5p14.3	9.501E-12	[CDH12]
7	7	91 921 079	92 111 471	190.4	7q21.2	2.0612E-10	CDK6 , <i>PEX1</i> , <i>GATAD1</i> , <i>DKFZP56400523</i> , <i>FAM133B</i>
8	8	11 346 688	11 659 701	313.0	8p23.1	9.0544E-10	<i>BLK</i> , <i>GATA4</i> , <i>C8orf13</i>
9	7	55 237 447	55 373 693	136.2	7p11.2	2.4109E-09	EGFR
10	17	35 102 118	35 136 335	34.2	17q12	3.8268E-09	ERBB2
11	13	72 528 937	72 770 614	241.7	13q22.1	1.4729E-07	<i>KLF5</i>
12	11	69 161 019	69 306 967	145.9	11q13.2	9.1737E-07	CCND1 , <i>FGF4</i> , <i>FGF19</i> , <i>ORAOV1</i>
13	7	115 987 034	116 178 774	191.7	7q31.2	0.00012527	<i>CAV1</i> , MET
Deletion							
1	3	60 447 451	60 472 964	25.5	3p14.2	3.4002E-41	FHIT
2	8	4 182 635	4 182 916	0.3	8p23.2	1.0797E-18	<i>CSMD1</i>
3	9	21 953 419	21 995 192	41.8	9p21.3	1.0299E-17	CDKN2A , CDKN2B
4	6	2 019 538	2 068 880	49.3	6p25.3	1.7756E-14	<i>GMDS</i>
5	16	77 269 209	77 293 232	24.0	16q23.1	5.4871E-12	<i>WWOX</i>
6	6	162 551 244	162 610 874	59.6	6q26	2.1056E-11	<i>PARK2</i>
7	13	47 806 677	47 809 375	2.7	13q14.2	3.3682E-11	RB1
8	5	58 436 441	58 569 237	132.8	5q11.2	1.6661E-10	<i>PDE4D</i>
9	9	9 524 063	9 675 303	151.2	9p23	1.2287E-09	<i>PTPRD</i>

Focal recurrent CNA (amplifications and deletions) identified by genomic identification of significant targets in cancer (GISTIC). Genes previously reported as oncogenes or tumour suppressor genes are highlighted in bold. Start and end indicates the boundary of the region identified. Length indicates size of each region identified. Q value represents the significance of the recurrent CNA region across all the gastric tumours. Genes in peak, genes covered by the corresponding region, a square bracket indicates that the gene lies immediately adjacent to the peak.




Figure 2 Mutually exclusive and co-amplified genomic alterations. (A) Focal regions exhibiting mutually exclusive patterns of genome amplification. Chromosomal diagrams were created using Circos software.³⁶ Circular tracks from outside to in: genomic positions by chromosomes (black lines are cytobands, red lines are centromeres); summarised CNA values in gastric tumours, summarised CNA values in normal gastric samples. Blue lines indicate pairs of focal regions (genes) exhibiting significant patterns of mutually exclusive genomic amplification identified by dimension reduction permutation (DRP) analysis ($p < 0.05$; *EGFR/KRAS*, $p = 0.05$). Genes involved in receptor tyrosine kinase (RTK)/RAS signalling are highlighted in red. (B) Focal regions exhibiting patterns of genomic co-amplification. Orange lines indicate pairs of focal regions (genes) exhibiting significant patterns of genomic co-amplification identified by DRP analysis ($p < 0.05$). Genes involved in RTK/RAS signalling are highlighted in red. Supplementary table S3 (available online only) provides a complete list of significant mutually exclusive and co-alteration relationships for amplifications and deletions.

KRAS/ERBB2 and *KRAS/FGFR2*, respectively), while tumours exhibiting *MET* amplifications were distinct from tumours with *FGFR2* amplifications ($p = 0.03$; figure 2A and supplementary table S3, available online only). Likewise, *GATA4*, *GATA6* and *KLF5* were significantly co-amplified with *MYC* (*KLF5*: $p = 0.0005$; *GATA4*: $p = 0.008$; *GATA6*: $p = 0.01$), while *KLF5* and *GATA4* amplifications were mutually exclusive to one another ($p = 0.01$).

Other notable ITR included a significant co-amplification interaction between *EGFR* and *MYC* ($p = 0.002$) and between *ERBB2* and *CCNE1* ($p = 0.05$) (figure 2B), a co-amplification pattern recently linked to trastuzumab resistance in breast cancer.³⁷ Taken collectively, these results support the existence of a complex functional network of ITR in gastric cancer. They provide evidence that instead of each target behaving independently from one another, the presence of one target in a gastric cancer is likely to exert a profound influence on the repertoire of other targets expressed in that same tumour.

Genomic alterations in RTK signaling genes—frequent, mutually exclusive and associated with patient survival in gastric cancer

Motivated by the clinical success of trastuzumab and the availability of other RTK-targeting drugs in the gastric cancer translational pipeline,³⁸ we decided to characterise the RTK genomic alterations and their impacts on patient outcome. A heat-map representation of the SNP array data confirmed that the four amplified RTK (*FGFR2*, *ERBB2*, *EGFR* and *MET*) were

mutually exclusive to one another (figure 3A). In addition, *KRAS* genomic amplifications were also mutually exclusive to the other RTK (figure 3A), suggesting these five components may activate the same downstream pathway in gastric cancer (see supplementary figure S5, available online only). The *KRAS* amplifications are examined in more detail in the next section.

Taken collectively, RTK/RAS genomic amplifications occurred in approximately 37% of the entire gastric cancer cohort (figure 3B). The most frequently amplified RTK/RAS component was *FGFR2* (9.3%), followed by *KRAS* (8.8%), *EGFR* (7.7%) and *ERBB2* (7.2%). Of 72 tumours exhibiting amplification in at least one RTK/RAS component, 73.6% (53/72) exhibited amplification of only one component, and 26.4% (19/72) tumours exhibited high level amplification of one component with low level amplification of another. Only two tumours exhibited high level amplification of two RTK/RAS components (black arrows in figure 3A). Taken collectively, these results suggest that 37% of the gastric cancer population is thus potentially targetable by a RTK/RAS-directed therapy.

To assess the prognostic impact of RTK amplifications in gastric cancer, we performed a survival analysis comparing the clinical outcome of patients bearing tumours with RTK amplifications compared with patients with tumours lacking RTK amplification. In a univariate analysis, patients with RTK amplified tumours (*FGFR2*, *ERBB2*, *EGFR*, *MET*) experienced poor survival outcome compared with patients with RTK amplification-negative cancers ($p = 0.01$, HR 1.636, 95% CI 1.101




Figure 3 Genomic alterations of receptor tyrosine kinase (RTK)/RAS signalling components in gastric cancer. (A) Mutually exclusive amplification patterns of RTK/RAS signalling components. In the heat-map, each row represents a different RTK/RAS signalling component. Each column represents an individual tumour exhibiting RTK/RAS amplification (72 tumours). The red colour gradient (top right) highlights the degree of copy number amplification. Black arrows highlight two tumours exhibiting high level amplifications in two RTK/RAS components. (B) Overall frequency of RTK/RAS genomic alterations in gastric cancer. The pie chart displays the different gastric cancer subgroups exhibiting RTK/RAS amplification. Gastric cancers exhibiting at least one RTK/RAS amplification event comprise a collective 37% of the gastric cancer cohort analysed. (C) Kaplan–Meier survival analysis comparing outcomes of patients with tumours exhibiting RTK amplification (either *FGFR2*, *ERBB2*, *EGFR*, or *MET*) amplification to patients with tumours lacking RTK amplification. Patients with tumours exhibiting focal *KRAS* amplifications were included in analysis, and fall into the RTK low/no CNA group. Overall survival was used as the outcome metric. (D) Kaplan–Meier survival analysis comparing outcomes of patients with tumours exhibiting *KRAS* amplification (15 patients) to patients with non-RTK/*KRAS*-amplified tumours. Overall survival was used as the outcome metric. The inset photo displays a patient tumour (ID 49375233) with *KRAS* amplification confirmed by fluorescence in-situ hybridisation (FISH) analysis (blue, DAPI nuclear stain; green, *KRAS* FISH probe; red, centromere 12 probe).

to 2.432; figure 3C). Moreover, in multivariate Cox regression models including RTK amplification status, stage, grade and treatment status (surgery alone or 5-FU adjuvant chemotherapy), RTK amplification status was shown to be an independent prognosis predictor ($p=0.01$, HR 1.966, 95% CI 1.180 to 3.279; see supplementary table S4a, available online only). The adverse prognosis of RTK-amplified gastric cancers was also largely independent of chromosomal instability ($p=0.07$), indicating that it is not a mere consequence of increased aneuploidy (see supplementary table S4a, available online only).⁵⁹

To evaluate individual RTK, we performed a follow-up univariate Cox model analysis considering the four different amplified RTK (*FGFR2*, *ERBB2*, *EGFR* and *MET*) as independent factors. Patients with *ERBB2*-amplified tumours and *MET*-amplified tumours were found to exhibit the worst prognosis

(*ERBB2*: $p=0.0006$, HR 2.824, 95% CI 1.558 to 5.119; *MET*: $p=0.002$, HR 2.744, 95% CI 1.190 to 6.327; see supplementary table S4b, available online only). The adverse prognostic impact of *ERBB2* amplification was also observed in a multivariate Cox model with adjustment for tumour stage and grade (see supplementary table S4c, available online only).^{6 7} Therefore, among the four different RTK, *ERBB2* amplifications appear to exert the strongest prognostic impact in gastric cancer.

KRAS-genomic amplifications highlight a previously underappreciated gastric cancer subgroup

KRAS amplifications were frequently observed in our series, occurring in 9% of patients. This finding is of interest, because canonical activating mutations in *KRAS* at codons 12 and 13 are strikingly infrequent in gastric cancer, unlike other

gastrointestinal cancers (eg, colorectal and pancreatic cancer).^{40 41} Confirming these earlier studies,⁴¹ the *KRAS* mutation rate in our own series was extremely low—among 139 gastric cancers genotyped for *KRAS* codon 12 and 13 mutations, only one tumour exhibited a *KRAS* mutation (G13D in 069LYK). We thus hypothesised that *KRAS* genome amplification, rather than mutation, may represent a predominant mechanism for *KRAS* activation in gastric cancer.

To obtain additional evidence that *KRAS* genomic amplifications represent a distinct gastric cancer molecular subgroup, we performed a Kaplan–Meier survival analysis comparing outcomes of patients with *KRAS*-amplified samples versus patients with tumours lacking RTK or *KRAS* amplification. Patients with *KRAS*-amplified tumours exhibited significantly poorer prognosis ($p=0.01$, HR 2.158, 95% CI 1.172 to 3.971; figure 3D). Supporting the robustness of this survival association, similarly significant associations were observed when patients with *KRAS*-amplified tumours were compared against patients lacking *KRAS* amplification but irrespective of RTK amplification, or when the copy number threshold defining *KRAS* amplification was relaxed ($p=0.06$, HR 1.744, 95% CI 0.973 to 3.127; $p=0.01$, HR 1.665, 95% CI 1.114 to 2.488; see supplementary figure S6, available online only).

To benchmark the prognostic effect of *KRAS* amplification against other RTK, we applied a univariate Cox regression model consisting of all five genes. Similar to *ERBB2* and *MET* amplifications, gastric cancer patients with *KRAS* amplifications also exhibited significantly worse prognosis compared with patients with tumours lacking either RTK or *KRAS* amplifications ($p=0.02$, HR 2.116, 95% CI 1.155 to 6.940; see supplementary table S5a, available online only); however, this association may be related to tumour stage ($p=0.2$, HR 1.455, 95% CI 0.790 to 2.682; see supplementary table S5b, available online only).

Finally, to provide functional evidence that *KRAS* genomic amplification represents an important ‘driver’ event in *KRAS*-amplified gastric cancers, we performed genetic knockdown experiments. Small interfering RNA-mediated knockdown of *KRAS* in *KRAS* amplified and *KRAS*-mutated gastric cancer cell lines caused significant reductions in proliferation but not in *KRAS* wild-type lines, supporting an earlier report⁴¹ (see supplementary figure S7, available online only). These results suggest that *KRAS* amplification in gastric cancer probably defines a specific subgroup of poor prognosis patients for which *KRAS* signalling in tumours is critical.

***FGFR2* amplifications in gastric cancer: relationships to gene expression, clinical outcome and drug sensitivity**

FGFR2 was being amplified in 9–10% of gastric cancers in our series (table 1). Consistent with *FGFR2* being the main driver of amplification in this locus, intersection of the amplification regions across 20 *FGFR2*-amplified tumours confirmed that *FGFR2* was the sole gene in this region exhibiting common copy number gain (figure 4A). Validating the SNP data, a quantitative PCR analysis using primers directed towards *FGFR2* confirmed that samples with high *FGFR2* qPCR values were associated with *FGFR2* amplification. ($p=0.0006$, Fisher’s test; see supplementary figure S8, available online only). FISH analysis using BAC probes targeting *FGFR2* also confirmed *FGFR2* gene amplification in patient tumours and cell lines, relative to a centromere 10 probe (figure 4B).

FGFR2 has previously been proposed as a potential therapeutic target in gastric cancer,³⁸ but little is known regarding the impact of *FGFR2* amplification on gene expression and other clinicopathological parameters. To investigate relationships

between *FGFR2* gene amplification and *FGFR2* gene expression, we analysed gene expression profile data for 156 of the 193 gastric cancers analysed by SNP arrays in this study, which we have described in an earlier report.⁴² *FGFR2*-amplified gastric cancers indeed exhibited significantly increased *FGFR2* gene expression levels (figure 4C and supplementary figure S9, available online only), when compared against a reference set of 100 normal gastric samples, or non-*FGFR2*-amplified tumours (Kruskal–Wallis test $p=6.7e-9$, Wilcoxon test $p=1.7e-7$ (vs normal) and $p=1.9e-5$ (vs non-*FGFR2*-amplified gastric cancers). In comparison, *ATE1* and *BRWD2*, two genes located adjacent to *FGFR2* exhibited less significant levels of copy number/gene expression correlation ($p=0.004–0.3$, relative to normals; supplementary figure S10, available online only), further supporting *FGFR2* as the major driver gene in this region.

Examining clinicopathological variables, *FGFR2*-amplified gastric cancers did not exhibit any significant associations with histology (Lauren’s $p=0.8$, grade $p=0.8$ or tumour stage $p=0.9$) or patient survival ($p=0.8$, see supplementary table S4b, available online only). However, in an expanded gene expression dataset of 398 gastric tumours derived from four distinct cohorts of which the previous 156 gastric cancers form a subset (see supplementary information and supplementary table S6, available online only), high *FGFR2* expression (compared with normals, supplementary figure S11, available online only) was associated with poor survival outcome in a univariate analysis ($p=0.01$, HR 1.492, 95% CI 1.094 to 2.035; figure 4D). In a multivariate Cox regression model, samples with *FGFR2* high expression tended to exhibit borderline significance after adjusting for stage and grade ($p=0.08$, HR 1.321, 95% CI 0.966 to 1.807; see supplementary table S7, available online only). This result suggests that *FGFR2* overexpression in gastric cancer may be of prognostic relevance.

Dovitinib (TKI258) is an investigational multitargeting oral tyrosine kinase inhibitor with potent inhibitory activity against bFGF receptors 1, 2, 3, VEGF receptors 1, 2, 3, PDGFR and *c-KIT*.^{43 44} In preclinical models, dovitinib has exhibited anti-tumour activity in *FGFR1*-amplified breast cancer,⁴⁵ and in several phase I clinical trials has shown good therapeutic profiles in human patients.^{46 47} To test the potential efficacy of dovitinib in *FGFR2*-amplified gastric cancer, we treated *FGFR2*-amplified and non-amplified gastric cancer lines (figure 5A) with increasing dosages of dovitinib, to determine the GI50 concentration (the drug concentration required to cause 50% growth inhibition). We observed potent growth inhibitory activity of dovitinib specifically in *FGFR2*-amplified gastric cancer cell lines with GI50 dosages in the submicromolar range (KATO-III 0.12 μM ; SNU-16 0.17 μM , figure 5B). Decreased phosphorylation of *FGFR2*, ERK and AKT was also observed after 1 h of dovitinib treatment (figure 5C). Besides inhibiting cell proliferation, dovitinib treatment also induced a significant decrease in soft-agar colony formation in *FGFR2*-amplified lines (KATO III $p=0.002$; SNU16 $p=0.05$; figure 5D and supplementary figure S12, available online only). In a cell death assay, dovitinib treatment induced apoptosis, measured by caspase 3/7 activation, in SNU-16 cells after 24 h of treatment, but not in KATO III cells (figure 5E). These results suggest that dovitinib treatment can inhibit several pro-oncogenic traits in *FGFR2*-amplified lines, but additional factors may be required for *FGFR2*-amplified cells to undergo apoptosis upon dovitinib treatment.

To evaluate the efficacy of dovitinib in an in-vivo model, we performed drug treatment experiments using an *FGFR2*-amplified primary human gastric cancer xenograft model, comparing




Figure 4 *FGFR2* gene amplification and messenger RNA expression in gastric cancer. (A) Heat-map showing the *FGFR2* gene amplification region in individual gastric cancer samples (20 tumours). Each row indicates one gastric cancer sample with the amplified region in red. Intensity of the red bar indicates the level of copy number amplification. Genes located in this region are shown at the bottom. The intersection of these amplified regions covers only the *FGFR2* gene (red box, gene outlined at bottom). (B) *FGFR2* genomic amplification confirmed by fluorescence in-situ hybridisation (FISH). The photo displays a patient tumour (ID 21080055) with *FGFR2* amplification and two *FGFR2*-amplified cell lines KATO-III and SNU16 confirmed by FISH analysis. Green signals indicate the *FGFR2* FISH probe, red signals probes to centromere 10. (C) *FGFR2* gene expression in clinical specimens. *FGFR2* gene expression was compared across three categories, each represented by a box-plot: non-malignant gastric tissues (normal) (n=100); tumours exhibiting no/low *FGFR2* CNA (n=139); and tumours exhibiting high *FGFR2* CNA (n=17). mRNA comparisons were based on 156 gastric cancers in which gene expression data were available, representing a subset of the 193 gastric cancers analysed by single nucleotide polymorphism arrays. *FGFR2* gene expression was inferred from Affymetrix microarrays (*FGFR2* probe 211401_s_at). *FGFR2* mRNA levels are significantly higher in samples with *FGFR2* high CNA compared with the other two categories ($p=6.7e-9$, Kruskal–Wallis test). Tumours exhibiting *FGFR2* amplification exhibit significantly increased *FGFR2* gene expression compared with tumours exhibiting no/low *FGFR2* CNA or non-malignant samples ($p=1.9e-5$ and $1.7e-7$, Wilcoxon test). (D) Kaplan–Meier survival analysis comparing patients with tumours exhibiting high *FGFR2* gene expression, defined as twofold higher than the average *FGFR2* gene expression level in normal samples (72 tumours), with patients with tumours exhibiting low *FGFR2* gene expression (total 398 patients, the 156 patients analysed in figure 4C are a subset of these 398 patients). Overall survival was used as the outcome metric.

dovitinib responses with the positive control drug 5-FU. Mean tumour sizes of vehicle-treated mice reached 1163 mm^3 at day 25 post-treatment, while treatment with 5-FU at 20 mg/kg (qd \times 5/week \times 2 weeks, intraperitoneally) produced a reduced mean tumour size of 518 mm^3 (total growth inhibition 63%, $p=0.08$) after the same period. Importantly, treatment with dovitinib at 30 mg/kg and 50 mg/kg (qd \times 25 days, by mouth) significantly inhibited tumour growth compared with vehicle-treated tumours ($p=0.006$ and 0.002 , respectively), with final tumour sizes of 194 and 53 mm^3 , respectively, at day 25 post-treatment (figure 5F). Dovitinib may thus represent a promising subtype-specific therapy for *FGFR2*-amplified gastric cancers.

DISCUSSION

Here we report a high-resolution genomic analysis of a large cohort of gastric cancer primary tumours and cell lines delineating the most prevalent molecular targets in this disease. While earlier reports analysing gastric cancer copy number alterations have largely analysed small patient populations or used low-resolution technologies (eg, chromosomal CGH),^{22–26} these earlier studies were invaluable in benchmarking the reproducibility of our own data. For example, in a recent copy number analysis of 49 gastric cancers using Agilent 44k arrays,²⁷ concordant regions commonly identified in that study and ours include the frequent broad amplifications of chromosome 8 and




Figure 5 Sensitivity of *FGFR2*-amplified gastric cancer cell lines to dovitinib. (A) (Top) *FGFR2* reverse transcription PCR analysis of gastric cancer cell lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. (Bottom) *FGFR2* protein expression in lines. β -actin was used as a loading control. Cell lines KATOIII and SNU16 are observed to express elevated levels of *FGFR2* mRNA and protein. (B) Cell proliferation effects of dovitinib treatment. Dovitinib GI50 values for *FGFR2*-amplified and non-amplified cell lines. GI50, drug concentration required to cause 50% growth inhibition. GI50 values were calculated after 48 h dovitinib treatment. * $p < 0.05$ compared with non-amplified lines. Results are a mean of three independent experiments. (C) Molecular effects of dovitinib treatment. Cells treated with dovitinib at 50 nM, 100 nM and 500 nM concentrations for 1 h. Lysates were immunoprecipitated with *FGFR2* antibody MAB6841, and probed with 4G10 (phosphotyrosine detection) or MAB6841 for total *FGFR2*. Other antibodies included total and phospho-ERK, and total and phospho-AKT. Experiments were repeated a minimum of three independent times. (D) Dovitinib inhibits soft agar colony formation. *FGFR2*-amplified cells were treated with dovitinib at the GI50 concentration for each cell line (KATO-III 0.12 μ M; SNU-16 0.17 μ M) for 48 h, and soft-agar colony formation monitored over the subsequent 3–4 weeks. Data for KATO-III cells are provided, including representative colony plates. Similar results were observed for SNU16 (see supplementary figure S9, available online only). (E) Dovitinib induces caspase-3 activation. *FGFR2*-amplified cells were treated with increasing dovitinib concentrations, and apoptosis levels measured after 24 h using Caspase-Glo 3/7 assays. The y-axis represents the percentage of activation normalised against untreated controls. The results are a mean of triplicates \pm SD. Experiments were repeated three independent times. (F) Dovitinib inhibits tumour growth in a human primary gastric cancer xenograft model bearing *FGFR2* gene amplification. The mean tumour size of the vehicle-treated mice reached 1163 mm³ at day 25 post-treatment. Treatment with the positive control drug 5-FU at 20 mg/kg (qd \times 5/week \times 2 weeks, intraperitoneally) produced a mean tumour size of 518 mm³ (total growth inhibition 63%, $p = 0.08$) at the same time. Treatment with dovitinib at 30 mg/kg and 50 mg/kg (qd \times 25 days, by mouth) significantly inhibited tumour growth compared with vehicle-treated animals, with a mean tumour size of 194 and 53 mm³, respectively ($p = 0.006$ and 0.002, respectively, at day 25 post-treatment).

20, losses of chromosome 16 and amplified genes such as *ERBB2*, *EGFR*, *GATA4*, *MYC*, *KRAS* and *CCNE1*. However, reflecting the increased size (193 vs 49) and resolution (44 K vs 1.8 million SNP probes) of our study, we also detected amplifications of chro-

somes 18 and deletions of chromosome 6q, which were not detected in earlier work.^{22–27}

Using GISTIC, we identified 22 recurrently altered regions in gastric cancer that are likely to represent the most prevalent

molecular targets. For several of these targets, we further confirmed the SNP array results using a variety of orthogonal methodologies, including immunohistochemistry, FISH and qPCR. A survey of genes in the 22 altered regions revealed that they could be broadly partitioned into three major functional categories: RTK/RAS signalling (*FGFR2*, *KRAS*, *ERBB2*, *EGFR*, *MET*); transcriptional regulation (*MYC*, *GATA4*, *GATA6*, *KLF5*) and cell cycle control (*CCND1*, *CCNE1*, *CDK6*, *CDKN2A/B*, *RB*). As expected, many of these genes were already known to be associated with genomic alterations in gastric cancer.^{6 11 28 29} Critically, however, our analysis also identified several novel genes not previously known to be amplified or deleted in gastric cancer. For example, we observed for the first time frequent deletions of *PARK2*, a E3 ubiquitin ligase, in gastric cancer.⁴⁸ Mutations in *PARK2* have been associated with early-onset Parkinson's disease,⁴⁹ and more recently *PARK2* mutations and deletions have been observed in other cancers.⁵⁰ Another novel altered gastric cancer gene was *CSMD1*, a gene of uncertain function but that has been proposed as a tumour suppressor in breast cancer.⁵¹ Using immunohistochemistry, we confirmed that up to 40% of gastric cancers can exhibit *CSMD1* protein loss or reduced expression. Addressing the functions of these novel altered genes, given their frequency of alteration in gastric cancer, will probably be an important goal of future research work. In addition, our study also highlights interesting therapeutic opportunities—for example, the cyclin-dependent kinase *CDK6* was frequently amplified in our series, and small molecule-targeted inhibitors of CDK have been developed.⁵²

A notable finding in this study was that *GATA4*, *GATA6* and *KLF5* are frequently amplified in gastric cancer. Notably, *GATA4* amplifications in gastric cancer have also been observed by other groups.⁵³ Intriguingly, when compared against genes identified as amplified in other comparable copy number studies from glioblastoma, lung cancer and multiple cancer types,^{19–21} it appears that amplification of these three genes appears to be restricted to either gastric cancer or to other cancers related to gastrointestinal tract origin. It is possible that these genes may represent 'lineage-specific' oncogenes, a recently described class of cancer genes that enhance oncogenesis by reactivating lineage-specific survival mechanisms normally operative only in early embryonic development.⁵⁴ Examples of lineage survival oncogenes include *MITF* in melanoma, *TTF1/NKX2.1* in lung cancer,^{55 56} and *SOX2* in oesophageal and lung cancers.⁵⁷ Indeed, *GATA6* has recently been proposed to function as an amplified lineage-survival oncogene in pancreatic cancer,^{35 58} and *KLF5* has been shown to be expressed during early development in the cardiovascular system and gastrointestinal tract epithelium in the proliferating zone of intestinal crypts.^{59 60} These transcription factors may reflect the existence of an underlying transcriptional regulatory programme important for the maintenance of the gastric cancer phenotype. Interestingly, a recent genomic study from our group reported the discovery of two gastric cancer subtypes (G-INT and G-DIF) with distinct gene expression, clinical outcome and chemotherapy response features.⁶¹ We have since discovered that G-DIF gastric cancers appear to be significantly enriched in *GATA6* gene amplifications (Fisher's exact test, $p=0.04$), suggesting that *GATA6* may be associated with a specific molecular subtype of gastric cancer. From a therapeutic perspective, transcription factors are commonly regarded as 'undruggable'. It is possible, however, that some of these transcription factors may regulate the expression of key genes that are pharmacologically targetable. For example, *BCL2* has been described as a target of the *MITF* transcription factor frequently amplified in melanoma,⁶²

and *BCL2* inhibitor drugs are available. Such a strategy may represent one method to target amplified transcription factors indirectly.

Of major clinical significance was the observation that genes related to RTK/RAS signalling are frequently altered and mutually exclusive to one another in gastric cancer. First, because numerous targeted inhibitors directed against various components of the RTK/RAS pathway are already in clinical testing,^{4 9} these results raise the possibility that a substantial proportion (37% of gastric cancers) may be potentially targetable by a RTK/RAS-directed therapy. In essence, this finding dramatically increases the population of gastric cancer patients for which targeted treatments could be considered. Second, the mutually exclusive nature of these RTK/RAS alterations strongly suggests that the majority of gastric cancers are likely to have only a single RTK/RAS driver oncogene, thereby greatly simplifying the challenge of defining which RTK/RAS targeted inhibitor compound to allocate to which patient population. In terms of clinical trials, the mutually exclusive nature of the RTK/RAS alterations also renders it technically feasible to implement a multibiomarker-based trial,⁶³ in which multiple targeted compounds are tested in different biomarker-defined populations within a single trial design, as has been recently described for non-small-cell lung cancer (BATTLE trial).⁶⁴ Third, these results suggest that a much larger proportions of gastric cancers may be reliant on RTK/RAS signalling than previously appreciated, particularly if one notes that in this study alternative mechanisms of RTK/RAS activation were not considered, and for certain gastric cancers the presence of non-malignant cells may have reduced the sensitivity of RTK/RAS alteration detection. For example, in a recent kinome sequencing study, kinases related to MAPK signalling, a pathway downstream of *KRAS*, were identified as being the most significantly altered in gastric cancer.⁶⁵ Another alternative mechanism of RTK/RAS activation may also involve gene fusions, in which we recently described RAF-related gene rearrangements in gastric cancer.⁶⁶ Taken collectively, we believe that our finding that 37% of gastric cancers exhibit a RTK/RAS alteration should best be regarded as a lower limit, and are consistent with the notion that RTK/RAS signalling is a dominant oncogenic pathway in gastric cancer.

In our series, *FGFR2* was amplified at frequencies comparable to *ERBB2*, providing one of the first assessments of *FGFR2* gene amplification in primary gastric cancers. Interestingly, the smallest common peak of *FGFR2* amplification in the gastric cancers appears to centre around a 1.5 kb region in *FGFR2* intron 2, which overlaps a SNP locus associated with breast cancer susceptibility.⁶⁷ It is intriguing to consider whether the process of genomic amplification might also bias the expression of the *FGFR2* gene towards transcript isoforms (IIIc) that are pro-oncogenic.⁶⁸ We also found that in preclinical assays, dovitinib, a *VEGFR/FGFR2* inhibitor, can potently inhibit the growth of *FGFR2*-amplified gastric cancer cell lines and xenografts. In breast cancer, dovitinib has been found to exert effects primarily in *FGFR1*-amplified breast cancers, suggesting the importance of *FGFR*-related genome amplification in predicting dovitinib response.⁶⁹ *FGFR2* is thus likely to represent an attractive therapeutic target in gastric cancer. However, one question not addressed by our data is whether gastric cancers that lack *FGFR2* amplification, but nevertheless express *FGFR2*, will also be dovitinib responsive, as we also observed that a significant number of *FGFR2* copy-neutral tumours also exhibited elevated *FGFR2* expression levels relative to matched normal tissues, indicating that other mechanisms besides gene amplification can

also cause *FGFR2* upregulation in tumours. Notably, a recent study showed that *FGFR2* inhibition can potentially reverse chemoresistance in OCUM-2M gastric cancer cells, which are also *FGFR2* copy-number amplified.⁷⁰ We are currently addressing these questions by conducting a biopsy-mandated phase I/II trial at our centre, evaluating the efficacy of dovitinib in *FGFR2*-amplified and *FGFR2*-expressing gastric cancer samples.

Finally, our results highlight *KRAS* amplification (rather than *KRAS* mutation) as a prevalent event in gastric cancer. While *KRAS* amplifications have been reported in other cancers (eg, lung),⁷¹ these observations have been largely anecdotal, with emphasis directed towards more conventional codon 12 and 13 activating mutations. Consistent with *KRAS* activating as an important driver gene in amplified samples, patients in our series with *KRAS*-amplified gastric cancers exhibited poor prognosis, and in vitro, *KRAS*-amplified gastric cancer lines were sensitive to *KRAS* silencing, similar to *KRAS* mutated lines. The high frequency of *KRAS* amplifications in gastric cancer is probably a major reason why *KRAS* activating mutations are strikingly infrequent in gastric cancer.⁴¹ However, the exact mechanisms underlying this striking tissue-specific preference for *KRAS* amplification remain to be elucidated. Nevertheless, given recent data demonstrating that *KRAS*-mutated colon cancers are resistant to anti-EGFR therapies,⁷² and that *KRAS*-amplified tumours may be resistant to MEK1/2 inhibitors,⁷³ our findings strongly suggest that testing *KRAS* amplification status in tumours should be fully considered in any trials evaluating RTK-targeting compounds in gastric cancer.

In conclusion, our results provide for the first time a detailed molecular map of genomic alterations in gastric cancer, which has revealed several promising targets for subtype-specific therapies. Classifying gastric cancer patients by these signature genomic alterations may facilitate patient allocations to the most appropriate clinical trials, thereby maximising patient participation in combatting this lethal disease.

Author affiliations

¹Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore

²NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore

³Saw Swee Hock School of Public Health, National University of Singapore, Singapore

⁴Division of Medical Oncology, National Cancer Centre, Singapore

⁵Department of Physiology, National University of Singapore, Singapore

⁶Cellular and Molecular Research, National Cancer Centre, Singapore

⁷Department of Pathology, Singapore General Hospital, Singapore

⁸Neuroscience and Behavioral Disorders, Duke-NUS Graduate Medical School, Singapore

⁹School of Biological Sciences, Nanyang Technological University, Singapore

¹⁰Section of Ophthalmology and Neuroscience, Leeds Institute for Molecular Medicine, Leeds, UK

¹¹Novartis Oncology, East Hanover, New Jersey, USA

¹²Department of Medicine, National University Health System, Singapore

¹³National Cancer Institute Singapore, National University Health System, Singapore

¹⁴Department of Internal Medicine, Yonsei Cancer Centre, Yonsei, South Korea

¹⁵Cancer Genomics and Biochemistry Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia

¹⁶Department of Pathology and Tumour Biology, Leeds Institute for Molecular Medicine, Leeds, UK

¹⁷Cancer Science Institute of Singapore, National University of Singapore, Singapore

¹⁸Genome Institute of Singapore, Singapore

Contributors ND, LKG and PT wrote the paper. ND, LKG, HW, KD, JT, SZ, IBT, ZL, GG, HG and PT analysed the data. HW, KD, JT, SZ, ML, JW, GG, QYL, ALKT, DYSP and SR conducted the experiments. KHL, MMS, RL, FZ, KGY, HCT, WPY, HCC, SYR and AB contributed data and reagents. LKG, SB, HG, SR and PT supervised the research. The first two authors contributed equally to this study.

Funding This study was supported by NMRC grants TCR/001/2007, BMRC 10/1/24/19/655, BMRC-NMRC 10/1/33/19/676 and core grants from Duke-National

University of Singapore and the Cancer Sciences Institute of Singapore to PT. This work was also supported by an ASCO grant to IBT, a Singhealth talent development grant to IBT and Priscilla Ng and a Khoo discovery award (KDP/2008/0002 and KDP/2009/0006) to LKG.

Competing interests MMS and RL are employees of Novartis Pharmaceuticals Corporation. All other authors declare that they have no competing interests.

Patient consent Obtained.

Ethics approval Ethics approval was provided by the Institutional Research Ethics Review Committees of Singapore Health Services and the National University Hospital System.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. *Methods Mol Biol* 2009;**472**:467–77.
- Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. *Lancet* 2009;**374**:477–90.
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006;**24**:2137–50.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;**376**:687–97.
- Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008;**52**:797–805.
- Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. *Ann Oncol* 2005;**16**:273–8.
- Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. *Ann Oncol* 2008;**19**:1523–9.
- Weichert W, Röske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. *Lancet Oncol* 2008;**9**:139–48.
- Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. *J Clin Oncol* 2011;**29**:1271–9.
- Moser C, Lang SA, Stoeltzing O. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. *Anticancer Res* 2009;**29**:2031–42.
- Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer* 2010;**10**:116–29.
- Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and ErbB3 signaling for growth and survival. *Cancer Res* 2008;**68**:2340–8.
- Takeda M, Arai T, Yokote H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. *Clin Cancer Res* 2007;**13**:3051–7.
- Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;**455**:1069–75.
- Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature* 2002;**418**:934.
- Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell* 2007;**12**:395–402.
- Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A* 2007;**104**:20932–7.
- Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc Natl Acad Sci U S A* 2007;**104**:20007–12.
- Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. *Nature* 2007;**450**:893–8.
- Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;**455**:1061–8.
- Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;**463**:899–905.
- Tay ST, Leong SH, Yu K, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. *Cancer Res* 2003;**63**:3309–16.
- Peng DF, Sugihara H, Mukaiishi K, et al. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. *J Pathol* 2003;**201**:439–50.
- Tada M, Kanai F, Tanaka Y, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. *Cancer Sci* 2010;**101**:1261–9.
- Tsukamoto Y, Uchida T, Karnan S, et al. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. *J Pathol* 2008;**216**:471–82.

26. **Kimura Y**, Noguchi T, Kawahara K, *et al*. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. *Mod Pathol* 2004;**17**:1328–37.
27. **Rossi E**, Klersy C, Manca R, *et al*. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. *Hum Pathol* 2011;**42**:1937–45.
28. **Bizari L**, Borim AA, Leite KR, *et al*. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. *Cancer Genet Cytogenet* 2006;**165**:41–50.
29. **Hirono Y**, Tsugawa K, Fushida S, *et al*. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. *Oncology* 1995;**52**:182–8.
30. **Xiao YP**, Wu DY, Xu L, *et al*. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma. *World J Gastroenterol* 2006;**12**:3766–9.
31. **Aqeilan RI**, Kuroki T, Pekarsky Y, *et al*. Loss of WWOX expression in gastric carcinoma. *Clin Cancer Res* 2004;**10**:3053–8.
32. **He XS**, Su Q, Chen ZC, *et al*. Expression, deletion [was deletion] and mutation of p16 gene in human gastric cancer. *World J Gastroenterol* 2001;**7**:515–21.
33. **Schneider BG**, Pulitzer DR, Brown RD, *et al*. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. *Genes Chromosomes Cancer* 1995;**13**:263–71.
34. **Lee TL**, Leung WK, Chan MW, *et al*. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. *Clin Cancer Res* 2002;**8**:1761–6.
35. **Kwei KA**, Bashyam MD, Kao J, *et al*. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreaticobiliary cancer. *PLoS Genet* 2008;**4**: e1000081.
36. **Krzyszewski M**, Schein J, Birol I, *et al*. Circos: an information aesthetic for comparative genomics. *Genome Res* 2009;**19**:1639–45.
37. **Scaltriti M**, Eichhorn PJ, Cortés J, *et al*. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. *Proc Natl Acad Sci U S A* 2011;**108**:3761–6.
38. **Asaoka Y**, Ikenoue T, Koike K. New targeted therapies for gastric cancer. *Expert Opin Invest Drugs* 2011;**20**:595–604.
39. **Sanchez-Perez I**, Garcia Alonso P, Belda Iniesta C. Clinical impact of aneuploidy on gastric cancer patients. *Clin Transl Oncol* 2009;**11**:493–8.
40. **Lievre A**, Bachet JB, Le Corre D, *et al*. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006;**66**:3992–5.
41. **Mita H**, Toyota M, Aoki F, *et al*. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. *BMC Cancer* 2009;**9**:198.
42. **Ooi CH**, Ivanova T, Wu J, *et al*. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. *PLoS Genet* 2009;**5**:e1000676.
43. **Trudel S**, Li ZH, Wei E, *et al*. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood* 2005;**105**:2941–8.
44. **Lee SH**, Lopes de Menezes D, Vora J, *et al*. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. *Clin Cancer Res* 2005;**11**:3633–41.
45. **Dey JH**, Bianchi F, Voshol J, *et al*. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. *Cancer Res* 2010;**70**:4151–62.
46. **Sarker D**, Molife R, Evans TR, *et al*. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. *Clin Cancer Res* 2008;**14**:2075–81.
47. **Ocio EM**, Mateos MV, Maiso P, *et al*. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. *Lancet Oncol* 2008;**9**:1157–65.
48. **Bedford L**, Lowe J, Dick LR, *et al*. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. *Nat Rev Drug Discov* 2011;**10**:29–46.
49. **Healy DG**, Falchi M, O'Sullivan SS, *et al*. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case–control study. *Lancet Neurol* 2008;**7**:583–90.
50. **Veeriah S**, Taylor BS, Meng S, *et al*. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. *Nat Genet* 2010;**42**:77–82.
51. **Kamal M**, Shaaban AM, Zhang L, *et al*. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. *Breast Cancer Res Treat* 2010;**121**:555–63.
52. **Lapenna S**, Giordano A. Cell cycle kinases as therapeutic targets for cancer. *Nat Rev Drug Discov* 2009;**8**:547–66.
53. **Weiss MM**, Kuipers EJ, Postma C, *et al*. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. *Cell Oncol* 2004;**26**:307–17.
54. **Garraway LA**, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. *Nat Rev Cancer* 2006;**6**:593–602.
55. **Garraway LA**, Widlund HR, Rubin MA, *et al*. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005;**436**:117–22.
56. **Kwei KA**, Kim YH, Girard L, *et al*. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. *Oncogene* 2008;**27**:3635–40.
57. **Bass AJ**, Watanabe H, Mermel CH, *et al*. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet* 2009;**41**:1238–42.
58. **Alvarez H**, Opalinska J, Zhou L, *et al*. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. *PLoS Genet* 2011;**7**:e1001356.
59. **Ohnishi S**, Laub F, Matsumoto N, *et al*. Developmental expression of the mouse gene coding for the Kruppel-like transcription factor KLF5. *Dev Dyn* 2000;**217**:421–9.
60. **Conkright MD**, Wani MA, Anderson KP, *et al*. A gene encoding an intestinal-enriched member of the Kruppel-like factor family expressed in intestinal epithelial cells. *Nucleic Acids Res* 1999;**27**:1263–70.
61. **Tan IB**, Ivanova T, Lim KH, *et al*. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. *Gastroenterology* 2011;**141**:476–85; 485 e1–11.
62. **McGill GG**, Horstmann M, Widlund HR, *et al*. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. *Cell* 2002;**109**:707–18.
63. **Printz C**. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. *Cancer* 2010;**116**:3307–8.
64. **Kim ES**, Herbst RS, Wistuba II, *et al*. The BALLTE trial: personalizing therapy for lung cancer. *Cancer Discovery* 2011;**1**:44–53.
65. **Zang ZJ**, Ong CK, Cutcutache I, *et al*. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. *Cancer Res* 2011;**71**:29–39.
66. **Palanisamy N**, Ateeq B, Kalyana-Sundaram S, *et al*. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat Med* 2010;**16**:793–8.
67. **Hunter DJ**, Kraft P, Jacobs KB, *et al*. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet* 2007;**39**:870–4.
68. **Katoh Y**, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). *Int J Mol Med* 2009;**23**:307–11.
69. **Andre F**, *et al*. A multicenter, open-label phase II trial of dicitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. *J Clin Oncol* 2011;**29**: (ASCO meeting abstract):508.
70. **Qiu H**, Yashiro M, Zhang X, *et al*. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. *Cancer Lett* 2011;**307**:47–52.
71. **Wagner PL**, Stiedl AC, Wilbertz T, *et al*. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. *Lung Cancer* 2011;**74**:118–23.
72. **Van Cutsem E**, Köhne CH, Hitre E, *et al*. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;**360**:1408–17.
73. **Little AS**, Balmanno K, Sale MJ, *et al*. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. *Sci Signal* 2011;**4**:ra17.